Open AccessProjet Ra&D à l'Ecole d'Ingénieurs et d'Architectes de Fribourg Développement d'un Nouvel Agent Anti-SIDA: NU 1320
Author(s) -
Martine Poffet,
Jean-Marc Bourgeois
Publication year - 2004
Publication title -
chimia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.387
H-Index - 55
eISSN - 2673-2424
pISSN - 0009-4293
DOI - 10.2533/000942904777678370
Subject(s) - human immunodeficiency virus (hiv) , humanities , in vivo , chemistry , physics , virology , philosophy , medicine , biology , microbiology and biotechnology
The division of chemistry at the School of Engineering and Architecture of Fribourg is involved with the School of Engineering of Geneva in the development of a new drug for the treatment of AIDS. This recently discovered molecule, called NU 1320, has already shown a powerful antiviral activity. NU 1320 is a nonnucleoside inhibitor, which stops the formation of the retrotranscription complexe of the HIV-virus. The concentration of NU 1320 to inhibit 50% of viral replication is 10–6 nM: such a low concentration and the non-toxicity will prevent the occurrence of side effects for the patient. As a future potential HIV drug, the University of Applied Sciences of Western Switzerland (HES-SO) has invested in this research with the start of a project for the scale-up of this new antiviral molecule with the intention to perform in vivo tests.